Royalty Pharma revenue and financials
$56.44Change from previous close: −0.39%Absolute change: −$0.22
In the fiscal year ended December 2025, Royalty Pharma reported revenue of $2.38B (+5.06% year over year). Net income was $770.95M, a net margin of 32.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.06%
- 2025 vs 2024
- Net income growth
- −10.25%
- 2025 vs 2024
- Net margin
- 32.4%
- 2024: 37.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2,490 | 2,769 | 2,988 | 2,144 | 2,018 | 2,035 | 1,667 | 1,618 |
| Depreciation and amortization | 3.9 | 0.0 | 0.0 | 5.7 | 23.0 | — | — | — |
| Investing cash flow | -1,614 | -2,678 | -2,073 | -1,029 | -1,870 | — | — | — |
| Financing cash flow | -1,186 | 361 | -2,149 | -945 | 385 | — | — | — |
| Dividends paid | -378 | -376 | -358 | -333 | -285 | — | — | — |
| Share repurchases | -1,227 | -230 | -305 | 0.0 | 0.0 | 0.0 | -4.3 | 0.0 |
| Debt issued | 3,229 | 1,471 | 350 | 0.0 | 1,273 | — | — | — |
| Debt repaid | -2,275 | 0.0 | -1,350 | 0.0 | — | — | — | — |
| Net change in cash | -310 | 452 | -1,234 | 170 | 532 | — | — | — |
| Free cash flow | 2,490 | 2,769 | 2,988 | 2,144 | — | — | — | — |
| Levered free cash flow | -670 | -1,758 | -1,244 | -1,384 | -1,547 | — | — | — |